These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7890653)

  • 21. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.
    Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
    Biochemistry; 1994 Mar; 33(12):3643-8. PubMed ID: 8142362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
    Wang Q; Shaltiel S
    BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
    J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.
    Xue Y; Björquist P; Inghardt T; Linschoten M; Musil D; Sjölin L; Deinum J
    Structure; 1998 May; 6(5):627-36. PubMed ID: 9634700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex.
    Wilczynska M; Fa M; Ohlsson PI; Ny T
    J Biol Chem; 1995 Dec; 270(50):29652-5. PubMed ID: 8530349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-neutralizing ligands. Ligand-induced serpin polymerization.
    Egelund R; Einholm AP; Pedersen KE; Nielsen RW; Christensen A; Deinum J; Andreasen PA
    J Biol Chem; 2001 Apr; 276(16):13077-86. PubMed ID: 11278457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
    Egelund R; Schousboe SL; Sottrup-Jensen L; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(3):775-85. PubMed ID: 9342229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A concerted structural transition in the plasminogen activator inhibitor-1 mechanism of inhibition.
    Blouse GE; Perron MJ; Thompson JH; Day DE; Link CA; Shore JD
    Biochemistry; 2002 Oct; 41(40):11997-2009. PubMed ID: 12356300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.
    Sipley JD; Alexander DS; Testa JE; Quigley JP
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):2933-8. PubMed ID: 9096324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conformational studies of plasminogen activator inhibitor type 1 by fluorescence spectroscopy. Analysis of the reactive centre of inhibitory and substrate forms, and of their respective reactive-centre cleaved forms.
    Fa M; Bergström F; Karolin J; Johansson LB; Ny T
    Eur J Biochem; 2000 Jun; 267(12):3729-34. PubMed ID: 10848991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center.
    Sherman PM; Lawrence DA; Yang AY; Vandenberg ET; Paielli D; Olson ST; Shore JD; Ginsburg D
    J Biol Chem; 1992 Apr; 267(11):7588-95. PubMed ID: 1559996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
    Audenaert AM; Knockaert I; Collen D; Declerck PJ
    J Biol Chem; 1994 Jul; 269(30):19559-64. PubMed ID: 8034724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
    Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
    Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical and biophysical studies of reactive center cleaved plasminogen activator inhibitor type 1. The distance between P3 and P1' determined by donor-donor fluorescence energy transfer.
    Aleshkov SB; Fa M; Karolin J; Strandberg L; Johansson LB; Wilczynska M; Ny T
    J Biol Chem; 1996 Aug; 271(35):21231-8. PubMed ID: 8702896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The structure of a serpin-protease complex revealed by intramolecular distance measurements using donor-donor energy migration and mapping of interaction sites.
    Fa M; Bergström F; Hägglöf P; Wilczynska M; Johansson LB; Ny T
    Structure; 2000 Apr; 8(4):397-405. PubMed ID: 10801484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.
    Lin Z; Jiang L; Yuan C; Jensen JK; Zhang X; Luo Z; Furie BC; Furie B; Andreasen PA; Huang M
    J Biol Chem; 2011 Mar; 286(9):7027-32. PubMed ID: 21199867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of fluorescent probes to characterize conformational changes in the interaction between vitronectin and plasminogen activator inhibitor-1.
    Gibson A; Baburaj K; Day DE; Verhamme I; Shore JD; Peterson CB
    J Biol Chem; 1997 Feb; 272(8):5112-21. PubMed ID: 9030577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.
    Gong L; Liu M; Zeng T; Shi X; Yuan C; Andreasen PA; Huang M
    J Biol Chem; 2015 Oct; 290(43):25795-804. PubMed ID: 26324706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Localization of vitronectin binding domain in plasminogen activator inhibitor-1.
    Lawrence DA; Berkenpas MB; Palaniappan S; Ginsburg D
    J Biol Chem; 1994 May; 269(21):15223-8. PubMed ID: 7515053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.